Therefore, our results highlighted a key role for Treg cells in DLBCL progression and suggested that targeting ICOS/ICOSL pathway may be an alternative immunotherapy for DLBCL treatment. Here, ICOSLG is linked to diffuse large B-cell lymphoma.